Treatment of relapsed/refractory acute B-cell leukemia with BiTE-EV

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and efficacy of BiTE-EV in adults suffering from relapsed or refractory acute B-cell leukemia. Participants will receive BiTE-EV every other day for a duration of 1 to 2 months and will be required to maintain a diary documenting their symptoms throughout the treatment period. Follow-up visits will occur every four weeks for check-ups and assessments to monitor the treatment's effects and any potential side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria: Patients can be enrolled in the group only if they meet all of the following conditions:

* Patients with acute B lymphocytic leukemia who are clinically diagnosed as relapsed (relapsed after CAR-T treatment or relapsed after transplantation), refractory, or whose T cells cannot be used for the production of CAR-T cells.
* Tumor cells show positive expression of CD19 detected by flow cytometry or immunohistochemistry.
* The age is between 18 and 70 years old (inclusive).
* The expected survival period from the date of signing the informed consent form is greater than 3 months.
* The Eastern Cooperative Oncology Group (ECOG) performance status score is ≤ 2.
* The functions of vital organs should meet the following requirements:

  * The ejection fraction (EF) is \> 50%, and there is no significant abnormality in the electrocardiogram.
  * The peripheral oxygen saturation (SpO2) is ≥ 92%.
  * The serum creatinine (Cr) is ≤ 1.5 times the upper limit of normal (ULN).
  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are ≤ 5 times the upper limit of normal (ULN), and total bilirubin (TBil) is ≤ 3 times the upper limit of normal (ULN).
* Subjects with pregnancy plans must agree to take contraceptive measures before enrolling in the study and six months after the study. If the subject is pregnant or suspected to be pregnant, they should immediately notify the investigator.
* The subject or the guardian understands and signs the informed consent form.

Exclusion Criteria:If any one of the following conditions is met, the subject cannot be enrolled in the group:

* Complicated with other diseases that are not effectively controlled, including but not limited to persistent or poorly controlled infections, symptomatic congestive heart failure, unstable angina pectoris, arrhythmia, poorly controlled pulmonary diseases or mental disorders.
* Having other active malignant tumors.
* Complicated with severe infections that cannot be effectively controlled.
* Those who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb), and those with peripheral blood hepatitis B virus (HBV) DNA higher than the detection limit need to be excluded; those who are positive for hepatitis C virus (HCV) antibody and positive for peripheral blood HCV RNA need to be excluded; those with positive cytomegalovirus (CMV) DNA detection; those with positive peripheral blood Epstein-Barr virus (EBV) DNA detection.
* Those who are positive for human immunodeficiency virus (HIV) antibody test or positive for syphilis test.
* Having a history of severe allergy to biological products (including antibiotics).

Patients with relapsed after allogeneic hematopoietic stem cell transplantation who have experienced grade 3 - 4 acute graft-versus-host disease (GvHD).

* Female subjects who are pregnant or in the lactation period.
* Active autoimmune diseases that require systemic immunosuppressive treatment.
* Situations that the investigator believes may increase the risk of the subject or interfere with the test results.

Where it's running

• Beijing GoBroad Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Jing Pan
• Email: panj@gobroadhealthcare.com
• Phone: 8618911067969

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Cohort for people with chronic myelomonocytic leukemia

  This project will collect blood and bone marrow samples from adults with chronic myelomonocytic leukemia at diagnosis and during disease changes to create an anonymized biobank researchers can use to test new questions.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Amiens and 23 other locations · NCT07512882

• Triple-drug approach for AML using eganelisib with azacitidine and venetoclax

  This early-stage trial tests whether adding eganelisib to azacitidine and venetoclax can be safe and show signs of benefit in adults with acute myeloid leukemia.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07439211

• Guided spiritual care sessions for adults with acute leukemia

  This will test whether adding guided spiritual care sessions helps adults hospitalized for initial treatment of acute leukemia compared with standard inpatient spiritual care.

  Recruiting University of Chicago · Chicago, Illinois · NCT07405424

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.